Back to search results

Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Abroad (travel likely)RecruitingPHASE2

Conditions

Catecholaminergic Polymorphic Ventricular Tachycardia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Department of Cardiology, Oslo University Hospital, Oslo, Norway

    Contact: Study coordinator (Ida Skrinde Leren, MD PhD) · b31868@ous-hf.no · 0047 230 700 00
Study leads

  • Rizwan Hussain, MD PhD

    Study Director

    Agiana Pharmaceuticals AS

View source on ClinicalTrials.gov(opens in a new tab)